Answers are grounded in this paper and cite their sources.
Tirzepatide could control postprandial hyperglycemia even in cases with diminished β-cell function. This finding gives new insight into the treatment of older patients with diabetes. However, tilzepatide does not replace basal insulin in cases with diminished β-cell function and requires careful observation for sarcopenia.
No takes yet. Share an insight, caveat, or question.
Sawamura et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: